Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA1 | Q09470 | 4/20 | 0.49 |
| ▸ | KCNAB1 | Q14722 | 4/20 | 0.49 |
| ▸ | NAMPT | P43490 | 2/20 | 0.48 |
| ▸ | TMPRSS2 | O15393 | 6/20 | 0.47 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.46 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.43 |
| ▸ | ESR1 | P03372 | 2/20 | 0.43 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17969238 | 0.84 | TMPRSS2 (0.44) | KCNA1KCNAB1NAMPTTMPRSS2PTPN2 | |
| SCHEMBL6163822 | 0.84 | KCNA1 (0.72) | KCNA1KCNAB1TMPRSS2NPC1RAB9A | |
| SCHEMBL16634693 | 0.83 | NAMPT (0.62) | KCNA1KCNAB1NAMPTTMPRSS2PTPN2 | |
| SCHEMBL4789781 | 0.82 | ESR2 (0.66) | KCNA1KCNAB1NAMPTPTPN1ESR1 | |
| SCHEMBL16634766 | 0.82 | KDM4E (0.49) | KCNA1KCNAB1NAMPTTMPRSS2PTPN2 | |
| SCHEMBL17969232 | 0.81 | TMPRSS2 (0.44) | KCNA1KCNAB1NAMPTTMPRSS2PTPN2 | |
| SCHEMBL10398383 | 0.81 | PTPN1 (0.66) | NAMPTTMPRSS2PTPN2PTPN1PRMT5 | |
| SCHEMBL14067246 | 0.80 | NAMPT (0.55) | KCNA1KCNAB1NAMPTPTPN2PTPN1 | |
| SCHEMBL17969245 | 0.80 | TMPRSS2 (0.40) | KCNA1KCNAB1NAMPTTMPRSS2PTPN2 | |
| SCHEMBL17969239 | 0.80 | NAMPT (0.44) | KCNA1KCNAB1NAMPTTMPRSS2PTPN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220125814-A1 | CANCER COMBINATION THERAPIES UTILIZING A NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE INHIBITOR IN COMBINATION WITH A NICOTINAMIDE ADENINE DINUCLEOTIDE SALVAGE PATHWAY PRECURSOR | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2022-04-28 | — | — | US | disclosed |
| WO-2020191359-A1 | CANCER COMBINATION THERAPIES UTILIZING A NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE INHIBITOR IN COMBINATION WITH A NICOTINAMIDE ADENINE DINUCLEOTIDE SALVAGE PATHWAY PRECURSOR | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2020-09-24 | — | — | WO | disclosed |
| EP-3055304-A1 | NOVEL PYRIDYLOXYACETYL TETRAHYDROISOQUINOLINE COMPOUNDS USEFUL AS NAMPT INHIBITORS | Eli Lilly and Company (US) | 2016-08-17 | — | — | EP | disclosed |
| US-20160229835-A1 | NOVEL PYRIDYLOXYACETYL TETRAHYDROISOQUINOLINE COMPOUNDS USEFUL AS NAMPT INHIBITORS | ELI LILLY AND COMPANY | 2016-08-11 | — | — | US | disclosed |
| WO-2015054060-A1 | NOVEL PYRIDYLOXYACETYL TETRAHYDROISOQUINOLINE COMPOUNDS USEFUL AS NAMPT INHIBITORS | ELI LILLY AND COMPANY (US) | 2015-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220125814-A1 | CANCER COMBINATION THERAPIES UTILIZING A NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE INHIBITOR IN COMBINATION WITH A NICOTINAMIDE ADENINE DINUCLEOTIDE SALVAGE PATHWAY PRECURSOR | NAMPT, NADK, NNT | KCNA1 4451/4885KCNAB1 3873/4885NAMPT 1/4885 |
| US-20160229835-A1 | NOVEL PYRIDYLOXYACETYL TETRAHYDROISOQUINOLINE COMPOUNDS USEFUL AS NAMPT INHIBITORS | NAMPT, NAPRT, NNMT | KCNA1 3819/4885KCNAB1 3743/4885NAMPT 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.